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surgeries and other treatments hat they replace. Others will 
be expensive by any measure, reflecting their enormous 
research costs. These costs could create an ever-widening 
gap between those who can afford powerftd new medicines 
and those who cannot. 
REPLACEMENT HEARTS 
Swine hearts. Online discussions with a variety of author- 
ities in what is kosher under the dietary laws of Judaism and 
under the laws of Islam show little concern that replacing a
human heart with a swine heart would be religiously 
forbidden. Some do not consider surgery to be equivalent to 
eating. Most cite traditions that suspend such laws when 
necessary to save a life. 
Neo-organs. To grow a heart muscle, you start with a 
donated human egg cell, substitute genetic material from a 
cell taken from the person for whom you are growing the 
heart muscle, and grow the resulting embryo in a laboratory 
dish to the 100-cell blastocyst stage. Then, you strip off 
the outer layer of cells, disaggregate he inner cell mass, 
and grow it into a colony of embryonic stem ceils. Finally, 
you stimulate them chemically to differentiate as myo- 
cytes, heart muscle cells. 
Until you strip off the outer layer of the blastocyst, he 
embryo is a human clone. Implanted in a uterus, it could grow 
into a full human being. To some, this means that it is a full 
human being and should not be used for any purpose, no 
matter how noble. To others, it is only a potential human being 
and does not become a human unless it is implanted in a 
uterus. Much the same process has occurred without 
comment for decades in fertility clinics doing in-vitro 
fertilizations (a number of embryos are created; when one 
is successfully implanted, the others are destroyed). Yet 
the idea of using embryonic stem cells has already created 
controversy and is currently under congressional ban in 
any laboratory receiving federal funds. Some experiment- 
ers believe, however, that neo-organs can be grown from 
more mature cells--fibroblasts--thus avoiding this par- 
ticular problem. 
PATIENT DATA 
Turning medical records into digital data makes copying 
them far easier and arouses privacy concerns, much the same 
as the creation of genomic data. The main protection for 
smart cards is that they require special readers. The main 
protection for CD-ROM cards and cards with personal 
identification numbers for Web sites is the patient's physical 
possession of them. 
LIFE EXTENSION 
The idea of extending people's lives beyond what seems to 
be their natural limit is not supported by any ethical 
consensus. Many physicians consider their goal to be curing 
disease, easing pain and disability, and avoiding early 
death--not extending life. 
If methods of extending life prove to be feasible, then it is 
likely that they WIU be considered medicaBy unnecessary, like 
cosmetic surgery, and so will not be covered. This means that 
only the financiaUy well-offwill live longer--a situation that is 
sure to provoke a great deal of ethical debate. 
These ethical concerns are likely to slow research in certahl 
areas, delay the adoption of some techniques for general use, 
and help mold the eventual shape of the technologies that 
come into use over the next decades. Technology is not some 
neutral force set apart from people; it is an expression of human 
desires and world views through scientific means. 
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Because this article is more likely than most articles in the 
Journal of the American College of Cardiology to be read by 
members of the media and other noncardiologists, we 
provide definitions of a few of the technical terms used: 
Angiogenesis: growth of new arteries; incardiology, anglo- 
genesis typically refers to the use of new drugs, such as vascular 
endothelial growth factor (VEGF) to promote the growth of 
new cardiac arteries that supply the heart muscles with blood. 
Angioplasty:. various techniques to re-open arteries that have 
been narrowed orclosed by arterial plaque. 
Apoptosis: cell self-destruction. 
Catheters: long, wirelike instruments typically inserted 
into large arteries to do work in the heart or the arteries. 
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Fibri l lation: the random and ineffective firing of any of 
the four vessels that comprise the heart. 
Genomic: relating to the genome, the entire pattern of 
genes in the body; a genetic study would look at patterns 
passed own through generations in the genes; a genomic 
study, by contrast, would focus on patterns of genes 
expressing, or being suppressed, in any given state of 
health or disease. 
Glycosylation: a process by which glucose causes pro- 
teins to cross-link into longer and less flexible chains and 
networks; glycosylation is implicated in many of the 
common signs of aging, such as wrinkles, glaucoma, the 
plaques formed in the brains of Alzheimer's disease 
sufferers, and many of the complications of adult-onset 
diabetes mellitus. 
High-density l ipoprotein (HDL):  "good" cholesterol, 
which actually helps prevent cardiovascular p oblems. 
Interventionist techniques: techniques that work 
through long, thin catheters inserted through tiny inci- 
sions into arteries or veins, rather than by inserting larger 
instruments through incisions in the body. 
Low-density l ipoprotein (LDL):  "bad" cholesterol, 
which leads to the formation of plaque in arteries. 
Minimal ly invasive surgery: surgery conducted through 
small ports cut into the body; the surgeons use long tools 
with tiny video lenses, lights, or surgical instruments at 
the end. 
Myogenesis: growth of new muscle; in cardiology, myo- 
genesis typically refers to the attempt o create drugs that 
will promote the growth of new heart muscles to supple- 
ment muscles that have been damaged by myocardial 
infarction or other heart disease. 
Nanotechnology: the art and craft of creating molecular- 
scale machines. 
Proteomic: relating to the "proteome," the entire pattern 
of proteins in use in the body; while a genomic study 
would focus on patterns of genes expressing, or being 
suppressed, in any given state of health or disease, a 
proteomic study would look at the patterns of proteins 
that those genes are building. 
Restenosis: reclosing of arteries after angioplasty. 
Stents: mesh tubes placed in arteries to keep them open. 
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